Zomedica Corp. · OTC:ZOMDF
Zomedica — Investor Presentation (April 2024)
35 slides from Zomedica's investor presentation, Apr 13, 2024
Slide 1: Zomedica April 2024
ZOMEDICA April 2024
Slide 2: Advancing Animal Health & Veterinarian Success
Advancing Animal Health & Veterinarian Success 2
Slide 3: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 4: Zomedica's Mission
Zomedica’s Mission Bring innovative diagnostic and therapeutic technology to Veterinarians to improve the quality of care for the pet, the satisfaction of the pet parent, and the workflow, cash flow and profitability of the practice 4
Slide 5: Key Takeaways
Delivering Outstanding ResultsThrough Focused Execution Significant market opportunity to address critical animal health needs Existing portfolio comprised of truly innovative technology platforms Global commercial channel in place to drive widespread adoption Key Takeaways Opportunities to expand o
Slide 6: Trends in Animal Health Have Set the Stage for a Huge Opportunity
Trends in Animal Health Have Set the Stage for a Huge Opportunity Pet Ownership is Increasing >23M U.S households who adopted a pet during the pandemic1 Pet Owners Are Getting Younger ~50% % Gen-Z U.S dog-owning households with one or more dogs under the age of two2 $62 B The Human-Animal Bond is In
Slide 7: Zomedica At A Glance
Zomedica At A Glance ProvenTrack Record of $2.5B Total Annual Recurring Revenue Addressable Market1 Financial Performance ~28% Therapeutic Devices FY23 Revenue Growth2 Therapeutic Diagnostics Devices ~252% Diagnostics FY23 YoY Revenue Growth2 Addressing two of the fastest growing segments of Animal
Slide 8: Zomedica Has the Opportunity to Service A Multi-Billion Dollar Market
Zomedica Has the Opportunity to Service A Multi-Billion Dollar Market U.S. Customer Base U.S. Total Annual Serviceable Market 4,450 Recurring Revenue Opportunities Equine or Mixed Practices $500 M $1,500 M $290 M $150 M TRUVIEWTM TRUFORMA® Assisi® PulseVet® $40 M VetGuardian® = $2.5 B Total Annual M
Slide 9: Our Portfolio is Well-Positioned to Address Critical Animal Health Needs
Our Portfolio is Well-Positioned to Address Critical Animal Health Needs Therapeutic Devices ZOM•Dx Accelerate Healing, Reduce Pain Cutting-Edge Diagnostic Technology By Delivering Innovation to Veterinarians and Pet Parents, We Seek to Improve: 1 The quality of 2 The satisfaction 3 Veterinarian 4 V
Slide 10: Zomedica Has Driven Sustained Growth With a Strong Financial Profile
Zomedica Has Driven Sustained GrowthWith a Strong Financial Profile Total Revenue ($000’s) $7,337 Financial Strength $6,157 $6,347 $6,020 $5,482 >33% $4,776 $4,081 $4,246 FY 2023 YoY Revenue Growth1 $3,751 2023: $25.2 million 2022: $18.9 million 2021: $4.1 million ~69% Gross Margins 1 $14 $16 $23 1Q
Slide 11: Delivering Product Innovation
Delivering Product Innovation 11
Slide 12: R&D: Core Technology Capabilities Set the Stage for Continued Innovation
R&D: CoreTechnology Capabilities Set the Stage for Continued Innovation TRUVIEWT Product Line Launch VetGuardian Product Line Launch Assisi Product Line Launch PulseVet Product Line Launch TRUFORMA Assay Launch Product Line Launch Assay Launch Assay Launch Assay Launch cPL Canine eACTH fT4 Equine eA
Slide 13: Therapeutic Devices: PulseVet Shock Wave Device
Total Available Annual Market (US) Therapeutic Devices: PulseVet®ShockWave Device Recurring Revenue $150 M Capital Revenue $1,000 M The Global Leader in Shock Wave Technology Clinically proven to enhance the quality & speed of healing in various musculoskeletal indications, from ligament and tendon
Slide 14: Therapeutic Devices: Assisi Devices
Therapeutic Devices: Assisi® Devices Total Available Annual Market (US) $290M Assisi tPEMF therapy Complements PulseVet Shock Wave therapy at Home Assisi Loop® & Assisi Loop Lounge® Recently Launched Line Extensions • Sold for pain and inflammation from OA, and • DentaLoop® device indicated for gum
Slide 15: ZOM•Dx: TRUVIEW Microscope
ZOM•Dx:TRUVIEW Microscope Total Available Annual Market (US) $500 M Digital Cytology Platform & Pathology Services Innovative digital imaging system with LiquiView liquid lens optics provide best-in- class visualization with TRUprep fully automated slide prep • First-in-class automated slide prepara
Slide 16: ZOM•Dx: TRUFORMA Devices
ZOM•Dx:TRUFORMA® Devices Total Available Annual Market (US) $1,500 M Reference Lab Accuracy at the Point of Care with TRUFORMA Diagnostic Platform Disposable cartridge preloaded with reagents Timely and accurate results Minimizes sample prep & simplifies workflow Supports practitioner’s ability to d
Slide 17: ZOM•Dx: TRUFORMA Assay Development
ZOM•Dx:TRUFORMA®Assay Development On the Market In Development Opportunities Currently Available Expanding into high-value Becoming a broad-based Point-of Care solution Point-of-Care solution Endocrine Panel • Canine TSH (cTSH) • Feline TSH (fTSH)1 Reproduction • Canine Total T4 (TT4) • Canine Proge
Slide 18: ZOM•Dx: VetGuardian Pet Monitoring Device
Total Available Market (US) ZOM•Dx:VetGuardian® Pet Monitoring Device Annual Recurring Revenue $40 M Capital Revenue $465 M Wireless Remote Monitoring System Ensure vulnerable pets are efficiently monitored 24-hour no touch vital signs monitoring capability provides improved care for pet patients, e
Slide 19: R&D: Supporting Improved Pet Care Through Digital Technology Solutions
R&D: Supporting Improved Pet CareThrough DigitalTechnology Solutions myZomedica ® A Hub for Clinical & Customer Experiences Allows our veterinary partners to engage with us beyond just test results • A stage for delivering clinical decision support • An eCommerce platform for streamlining the reorde
Slide 20: R&D: The Next Phase of Product Innovation to Drive Increased Utilization
R&D:The Next Phase of Product Innovation to Drive Increased Utilization Therapeutic Devices ZOM•Dx New Indications New Assays • PulseVet®, Assisi® platforms: Supporting • TRUFORMA® platform : Continue to add new high- clinical studies to identify new technology value assays applications • Focused on
Slide 21: Driving Widespread Adoption
Driving Widespread Adoption 21
Slide 22: Marketing: Leveraging a Unique Omnichannel Strategy to Drive Adoption
Marketing: Leveraging a Unique Omnichannel Strategy to Drive Adoption Leading with Multi-Channel Sales Focus Market Development Is The Key Internal Sales Focusing on increasing awareness and understanding Force of Zomedica’s portfolio by: U.S. and Int’l #1 Maximizing Customer Education Initiatives e
Slide 23: Sales: Leveraging a Well-Established Commercial Infrastructure
Sales: Leveraging a Well-Established Commercial Infrastructure to Drive Adoption Direct Salesforce Distribution Networks Canada & Japan Europe Australia Middle East Mexico Led by Established U.S. Direct Salesforce Supplementing U.S. Efforts With Distribution Network • Selling Core Products: PulseVet
Slide 24: Sales: Direct Sales Channel Driving Incremental Gains
Sales: Direct Sales Channel Driving Incremental Gains Targeting key Veterinarian practices by segment Veterinary Channel Using distribution relationships to better access new customers PulseVet® system: Leveraging the exceptional acceptance in the equine market to drive adoption in small animal spac
Slide 25: Achieving Operational Efficiencies
Achieving Operational Efficiencies 25
Slide 26: Manufacturing: Best-in-Class Capabilities Across Two U.S. Facilities
Manufacturing: Best-in-ClassCapabilities AcrossTwo U.S. Facilities Zomedica Global Manufacturing & Distribution Center, South Zomedica Global Manufacturing & Distribution Center, North Roswell, GA Plymouth, MN • Established in Roswell, Georgia in August, 2022 • Acquired in Plymouth, MN in October, 2
Slide 27: Manufacturing: Driving Leverage Through Operational Efficiencies
Manufacturing: Driving LeverageThrough Operational Efficiencies Key Enablers of Improving Operational Efficiency Ability to scale Roswell facility by 5x to meet future growth targets Through prior investments, Zomedica Full integration of Qorvo Biotechnologies’ R&D and manufacturing facility is posi
Slide 28: Scaling Through Acquisition
Scaling Through Acquisition 28
Slide 29: Zomedica's Long Term Growth Strategy
Zomedica’s LongTerm Growth Strategy Over the past three years, Zomedica has been driving a three-part growth strategy 1 businesses Acquire high-potential, high-growth that benefit the patient, 2 Integrate these businesses efficiently 3 Leverage Zomedica’s commercial to leverage best-in-class capabil
Slide 30: Innovation Worthy of Investment
InnovationWorthy of Investment Track record of identifying and efficiently acquiring highly differentiated, high potential technologies that elevate the standard of care in Animal Health • We’ve created a best of the best portfolio with strong growth, high margins, and huge TAM’s • Many are still in
Slide 31: Producing Compelling Results
Producing Compelling Results 31
Slide 32: Financial Highlights
Financial Highlights Annual Revenue ($M) Gross Margin 75% 74% FY 2024 Guidance 73% 71% 70% $35.0 68% 67% 69% 69% $31.0 $25.2 +39% +23% $18.9 Historical margins ~70% with +33% slight decrease in recent quarters +358% due to mix of new products and $4.1 acquisition / transition related activities 2021
Slide 33: Future Growth Driven by Continued Commercial Execution
Future Growth Driven by Continued Commercial Execution FY 2024 Revenue Guidance Range Bridge ($M) 1 Key Growth Drivers +39% • Momentum from a larger, more mature salesforce +$4 $35 YoY Growth at High-End • Further penetrating companion animal veterinarian practices • Select international market expa
Slide 34: Key Takeaways
Delivering Outstanding ResultsThrough Focused Execution Significant market opportunity to address critical animal health needs Existing portfolio comprised of truly innovative technology platforms Global commercial channel in place to drive widespread adoption Key Takeaways Opportunities to expand o
Slide 35: Q&A
O&A ZOM LISTED <— ZOMEDICA NYSE AMERICAN